Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

0.2550 +0.0051 (+2.04%)
Streaming Delayed Price Updated: 9:53 AM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 82,758
Open 0.2590
Bid (Size) 0.2495 (2)
Ask (Size) 0.2550 (2)
Prev. Close 0.2499
Today's Range 0.2415 - 0.2600
52wk Range 0.2271 - 3.392
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool 
Via News Direct
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-78.21%
-78.21%
1 Month
-33.14%
-33.14%
3 Month
-54.46%
-54.46%
6 Month
-75.61%
-75.61%
1 Year
-92.15%
-92.15%

More News

Read More
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
From Mainz BioMed NV
Via GlobeNewswire
Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test
Via News Direct
Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones
Via News Direct
Exposures Product Safety
Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
Via News Direct
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
Via Benzinga
Exposures COVID-19
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
From Mainz BioMed NV
Via GlobeNewswire
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
From Mainz BioMed NV
Via GlobeNewswire
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
Via Benzinga
Exposures COVID-19
Mainz Biomed Provides Half Year 2024 Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Via Benzinga
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
Via News Direct
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
Via News Direct
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Results of 2024 Annual General Meeting
From Mainz BioMed NV
Via GlobeNewswire
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
From Mainz BioMed NV
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.